Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of 177Lu-NYM032 in PSMA-positive taxane-naive progressive metastatic castration-resistant prostate cancer
CTR20262226Phase 2Active
- Sponsor
- Norroy Bioscience
- Start
- May 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NY108 in prostate cancer (PCa), sponsored by Norroy Bioscience. Started May 2026; status: active.
02
Drugs
NY108
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20262226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262226.